The role of complement in arterial hypertension and hypertensive end organ damage. (19th August 2020)

• Record Type: Journal Article
• Authors: Wenzel, Ulrich O.; Kemper, Claudia; Bode, Marlies
• Is Part Of: British journal of pharmacology. Volume 178:Number 14(2021)
• Page Start: 2849
• Page End: 2862
• Publication Date: 2020-08-19
• Subjects: arterial hypertension -- atypical hemolytic uremic syndrome -- C5aR1 -- C5aR2 -- C3aR -- C3 -- C1q -- malignantnephrosclerosis; Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.15171
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Increasing evidence indicates that hypertension and hypertensive end organ damage are not only mediated by haemodynamic injury but that inflammation also plays an important role. The complement system protects the host from a hostile microbial environment and maintains tissue and cell integrity through the elimination of altered or dead cells. As an important effector arm of innate immunity, it plays also central roles in the regulation of adaptive immunity. Thus, complement activation may drive the pathology of hypertension through its effects on innate and adaptive immune responses, aside from direct effects on the vasculature. Recent experimental data strongly support a role for complement in all stages of arterial hypertension. The remarkably similar clinical and histopathological features of malignant nephrosclerosis and atypical haemolytic uraemic syndrome suggest also a role for complement in the development of malignant nephrosclerosis. Here, we review the role of complement in hypertension and hypertensive end organ damage. Linked Articles: This article is part of a themed issue on Canonical and non‐canonical functions of the complement system in health and disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.14/issuetoc